Medina-Franco H, Salgado-Nesme N, Zerón-Medina-Cuairán J

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 390-394
Archivo PDF: 49.93 Kb.

RESUMEN

Introducción. La viabilidad y la precisión de la biopsia del ganglio centinela en los pacientes que han recibido quimioterapia neoadyuvante para el tratamiento del cáncer de mama continúa siendo un tema controversial. Material y métodos. Treinta y un pacientes con diagnóstico de carcinoma invasor de mama, en quienes se administró quimioterapia neoadyuvante, fueron sometidos a biopsia de ganglio centinela y disección axilar. Resultados. El ganglio centinela fue identificado exitosamente en 26 (83.8%) pacientes. El ganglio fue positivo para malignidad en nueve (34.6%) pacientes. Dos de los pacientes con ganglio centinela negativo presentaron ganglios positivos en el espécimen histopatológico final de la disección axilar (porcentaje de falsos negativos: 18%). Conclusiones. Los resultados obtenidos en nuestro estudio clínico prospectivo no apoyan el uso de la biopsia de ganglio centinela como un procedimiento preciso para predecir la positividad de los ganglios axilares.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30: 96-102.

2. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990; 82: 1536-45.

3. Bear HD, Anderson S, Smith R, Robidoux A, Kahlenberg MS, et al. A randomized trial comparing preoperative doxorubicin/ cyclophosphamide (AC) to preoperative AC followed by preoperative docetaxel (T) in patients with operable carcinoma of the breast: results of NSABP. SABCS 2004 (Abstract 26).

4. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operative breast cancer. J Clin Oncol 1998; 16: 2672-85.

5. Gianni L, Baselga J, Eiermann W, Guillen Porta V, Semiglazov, Garcia-Conde J, et al. First report of the European cooperative trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on localregional disease. Proc ASCO 2002 (Abstract 132).

6. Kaufmann M, Von Minckwitz G, Achim Rody. Preoperative (neoadjuvant) systemic treatment of breast cancer. The Breast 2005; 14: 576-81.

7. Von Minckwitz G, Raab G, Caputo A, Schuette N, Hilfrish J, Blohmer JU, et al. Doxorubicin with cyclophosphamide followed by Docetaxel weekly every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer. The Geparduo study of the German Breast Group. J Clin Oncol 2005; 23: 2676-85.

8. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical breast and bowel project protocol B-27. J Clin Oncol 2003; 21: 4165-74.

9. Tanis PJ, Nieweg OE, Valdes-Olmos RA, et al. History of sentinel node and validation technique. Breast Cancer Res 2001; 3: 109-12.

10. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectoymy for breast cancer. Ann Surg 1994; 220: 391-8.

11. Kuerer HM, Hunt KK. The rationale for integration of lymphatic mapping and sentinel node biopsy in the management of breast cancer patients receiving neoadjuvant chemotherapy. Semin Breast Dis 2002; 5: 80-7.

12. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma a meta-analysis. Cancer 2006; 106: 4-16.

13. Miltenburg DM, Miller C, Karamlou TB, Brunicardi FC. Metaanalysis of sentinel lymph node biopsy in breast cancer. J Surg Res 1999; 84: 138-42.

14. Fraile M, Rull M, Julian FJ, Fuste F, Barnadas A, Llatjos M, et al. Sentinel node biopsy as a practical alternative to axillary lymph node dissection in breast cancer patients: an approach to its validity. Ann Oncol 2000; 11: 701-5.

15. Péley G, Török K, Farkas E, et al. The feasibility and the role of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer. Magy Onkol 2006; 5: 19-23.

16. Nason KS, Anderson BO, Byrd DR, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000; 89: 2187-94.

17. Shen J, Glicrease MZ, Babiera GV, et al. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 2007; 109: 1255-63.

18. Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 2005; 93: 539-46.

19. Lyman G, Guiliano A, Somerfield M, Benson A, et al. American Society of clinical oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23: 7703-20.

20. Mamounas E, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 2005; 23: 2694-702.

21. Sharkey FE, Addington SL, Fowler LJ, Page CP, Cru AB. Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma. Mod Pathol 1996; 9: 893-900.

22. Vergara-Fernandez O, Cortés-González R, Medina-Franco H. Validation of sentinel node in breast cancer. Rev Invest Clin 2004; 56: 309-13.

23. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997; 349: 1864-7.

24. Sabel MS, Schott AF, Kleer CG, Merajver S, Cimmino VM, Diehl KM, et al. Sentinel node biopsy prior to neoadjuvant chemotherapy. Am J Surg 2003; 186: 102-05.